Standard Biotools Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.79
- Today's High:
- $2.895
- Open Price:
- $2.85
- 52W Low:
- $0.92
- 52W High:
- $3.16
- Prev. Close:
- $2.85
- Volume:
- 191718
Company Statistics
- Market Cap.:
- $240.84 million
- Book Value:
- -1.433
- Revenue TTM:
- $105.45 million
- Operating Margin TTM:
- -77.52%
- Gross Profit TTM:
- $-1447000
- Profit Margin:
- -79.8%
- Return on Assets TTM:
- -12.82%
- Return on Equity TTM:
- -35.68%
Company Profile
Standard Biotools Inc had its IPO on 2003-07-29 under the ticker symbol LAB.
The company operates in the Healthcare sector and Diagnostics & Research industry. Standard Biotools Inc has a staff strength of 523 employees.
Stock update
Shares of Standard Biotools Inc opened at $2.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.79 - $2.9, and closed at $2.86.
This is a +0.35% increase from the previous day's closing price.
A total volume of 191,718 shares were traded at the close of the day’s session.
In the last one week, shares of Standard Biotools Inc have slipped by -6.23%.
Standard Biotools Inc's Key Ratios
Standard Biotools Inc has a market cap of $240.84 million, indicating a price to book ratio of 5.8691 and a price to sales ratio of 0.9876.
In the last 12-months Standard Biotools Inc’s revenue was $105.45 million with a gross profit of $-1447000 and an EBITDA of $-78442000. The EBITDA ratio measures Standard Biotools Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Standard Biotools Inc’s operating margin was -77.52% while its return on assets stood at -12.82% with a return of equity of -35.68%.
In Q2, Standard Biotools Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 47.3%.
Standard Biotools Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Standard Biotools Inc’s profitability.
Standard Biotools Inc stock is trading at a EV to sales ratio of 0.2288 and a EV to EBITDA ratio of -0.1534. Its price to sales ratio in the trailing 12-months stood at 0.9876.
Standard Biotools Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $355.83 million
- Total Liabilities
- $46.84 million
- Operating Cash Flow
- $40.13 million
- Capital Expenditure
- $838000
- Dividend Payout Ratio
- 0%
Standard Biotools Inc ended 2024 with $355.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $355.83 million while shareholder equity stood at $-113387000.00.
Standard Biotools Inc ended 2024 with $1.05 million in deferred long-term liabilities, $46.84 million in other current liabilities, 81000.00 in common stock, $-959979000.00 in retained earnings and $106.29 million in goodwill. Its cash balance stood at $142.30 million and cash and short-term investments were $142.30 million. The company’s total short-term debt was $8,495,000 while long-term debt stood at $60.66 million.
Standard Biotools Inc’s total current assets stands at $183.07 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $15.12 million compared to accounts payable of $6.09 million and inventory worth $22.08 million.
In 2024, Standard Biotools Inc's operating cash flow was $40.13 million while its capital expenditure stood at $838000.
Comparatively, Standard Biotools Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.86
- 52-Week High
- $3.16
- 52-Week Low
- $0.92
- Analyst Target Price
- $0.55
Standard Biotools Inc stock is currently trading at $2.86 per share. It touched a 52-week high of $3.16 and a 52-week low of $3.16. Analysts tracking the stock have a 12-month average target price of $0.55.
Its 50-day moving average was $2.56 and 200-day moving average was $2.04 The short ratio stood at 10.81 indicating a short percent outstanding of 0%.
Around 278.7% of the company’s stock are held by insiders while 6167.1% are held by institutions.
Frequently Asked Questions About Standard Biotools Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.